Evaluation Pembrolizumab (Keytruda): CADTH Reimbursement Advice: Sign: Together with chemotherapy, with the procedure of adult individuals with regionally recurrent unresectable or metastatic triple-negative breast cancer who may have not received prior chemotherapy for metastatic ailment and whose tumours express programmed mobile death-ligand 1 (